Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

bioAffinity Technologies, Inc. - Common Stock (NQ:BIAF)

0.2600 -0.0019 (-0.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 41,851,458
Open 0.2700
Bid (Size) 0.6745 (1)
Ask (Size) 0.6760 (36)
Prev. Close 0.2619
Today's Range 0.2404 - 0.2929
52wk Range 0.2404 - 3.163
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's going on in today's after hours session
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga

Performance

YTD
-72.3%
-72.3%
1 Month
-36.6%
-36.6%
3 Month
-72.0%
-72.0%
6 Month
-87.5%
-87.5%
1 Year
-87.6%
-87.6%

More News

Read More
bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
Case Study: bioAffinity Technologies’ CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer
From bioAffinity Technologies, Inc.
Via Business Wire
Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence
From bioAffinity Technologies, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Monday's session: top gainers and losers
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Traders are paying attention to the gapping stocks in Monday's session.
Via Chartmill
Physicians’ Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million
From bioAffinity Technologies, Inc.
Via Business Wire
Global Drug Screening Market Is Forecasted to Reach $19.5 Billion By 2029
Via FinancialNewsMedia
Topics Cannabis Death
Exposures Cannabis Death
Global Drug Screening Market Is Forecasted to Reach $19.5 Billion By 2029
From FN Media Group LLC
Via GlobeNewswire
bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Set for Continued Expansion in 2025
From bioAffinity Technologies, Inc.
Via Business Wire
Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
From bioAffinity Technologies, Inc.
Via Business Wire

Frequently Asked Questions

Is bioAffinity Technologies, Inc. - Common Stock publicly traded?
Yes, bioAffinity Technologies, Inc. - Common Stock is publicly traded.
What exchange does bioAffinity Technologies, Inc. - Common Stock trade on?
bioAffinity Technologies, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for bioAffinity Technologies, Inc. - Common Stock?
The ticker symbol for bioAffinity Technologies, Inc. - Common Stock is BIAF on the Nasdaq Stock Market
What is the current price of bioAffinity Technologies, Inc. - Common Stock?
The current price of bioAffinity Technologies, Inc. - Common Stock is 0.2600
When was bioAffinity Technologies, Inc. - Common Stock last traded?
The last trade of bioAffinity Technologies, Inc. - Common Stock was at 03/31/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.